sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
|
erythromycin
|
hexobarbital
|
INT
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s24
|
DDI-DrugBank.d522.s24.p1
|
May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;
|
cholestyramine
|
thiazide diuretics
|
EFFECT
|
Bendroflumethiazide_ddi.xml
|
DDI-DrugBank.d304.s0
|
DDI-DrugBank.d304.s0.p1
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
nortriptyline
|
risperidone
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p889
|
In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.
|
aminoglycoside
|
penicillins
|
EFFECT
|
Kanamycin_ddi.xml
|
DDI-DrugBank.d57.s0
|
DDI-DrugBank.d57.s0.p1
|
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
|
benzodiazepines
|
ergotamine
|
INT
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s10
|
DDI-DrugBank.d131.s10.p1
|
Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
|
TARCEVA
|
troleandomycin
|
ADVISE
|
Erlotinib_ddi.xml
|
DDI-DrugBank.d456.s1
|
DDI-DrugBank.d456.s1.p10
|
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of beta2-agonists.
|
Diuretics
|
beta2-agonists.
|
NONE
|
Formoterol_ddi.xml
|
DDI-DrugBank.d103.s4
|
DDI-DrugBank.d103.s4.p14
|
This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.
|
probenecid
|
bumetanide
|
MECHANISM
|
Bumetanide_ddi.xml
|
DDI-DrugBank.d331.s5
|
DDI-DrugBank.d331.s5.p0
|
Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.
|
lithium
|
ACE inhibitors
|
MECHANISM
|
Candesartan_ddi.xml
|
DDI-DrugBank.d547.s2
|
DDI-DrugBank.d547.s2.p7
|
Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
|
NSAIDs
|
lithium
|
MECHANISM
|
Mefenamic acid_ddi.xml
|
DDI-DrugBank.d400.s9
|
DDI-DrugBank.d400.s9.p4
|
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.
|
calcium-channel blockers
|
NSAIDs
|
NONE
|
Cerivastatin_ddi.xml
|
DDI-DrugBank.d141.s13
|
DDI-DrugBank.d141.s13.p17
|
Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.
|
Erythromycin
|
triazolam
|
MECHANISM
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s6
|
DDI-DrugBank.d397.s6.p0
|
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
|
SSRIs
|
5-HT1 agonists
|
EFFECT
|
Almotriptan_ddi.xml
|
DDI-DrugBank.d299.s6
|
DDI-DrugBank.d299.s6.p17
|
Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
|
meperidine
|
phenothiazines
|
NONE
|
Biperiden_ddi.xml
|
DDI-DrugBank.d401.s0
|
DDI-DrugBank.d401.s0.p24
|
It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
|
phenothiazines
|
LEVULAN KERASTICK
|
EFFECT
|
Aminolevulinic acid_ddi.xml
|
DDI-DrugBank.d379.s1
|
DDI-DrugBank.d379.s1.p24
|
Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for atracurium alone and 13.7 +/- 1.2 min for atracurium plus gentamycin.
|
atracurium
|
gentamycin
|
EFFECT
|
8542840.xml
|
DDI-MedLine.d90.s8
|
DDI-MedLine.d90.s8.p2
|
Anticoagulant therapy should be monitored, particularly during the first few weeks, after initiating therapy with BEXTRA in patients receiving warfarin or similar agents.
|
BEXTRA
|
warfarin
|
ADVISE
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s26
|
DDI-DrugBank.d328.s26.p2
|
Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
|
Bentiromide
|
chloramphenicol
|
INT
|
Bentiromide_ddi.xml
|
DDI-DrugBank.d537.s0
|
DDI-DrugBank.d537.s0.p2
|
Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45 (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
|
ergot alkaloid class
|
macrolide class
|
MECHANISM
|
Dihydroergotamine_ddi.xml
|
DDI-DrugBank.d410.s5
|
DDI-DrugBank.d410.s5.p21
|
The use of dextromethorphan hydrobromide may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.
|
dextromethorphan hydrobromide
|
antihistamines
|
EFFECT
|
Guaifenesin_ddi.xml
|
DDI-DrugBank.d398.s2
|
DDI-DrugBank.d398.s2.p1
|
It is concluded that ketamine is not a short-acting drug and that concomitant use with halothane would be expected to prolong further the duration of its action on the central nervous system.
|
ketamine
|
halothane
|
EFFECT
|
1115367.xml
|
DDI-MedLine.d16.s6
|
DDI-MedLine.d16.s6.p0
|
As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.
|
potassium-sparing diuretics
|
spironolactone
|
NONE
|
Losartan_ddi.xml
|
DDI-DrugBank.d30.s8
|
DDI-DrugBank.d30.s8.p0
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
phenytoin
|
disulfiram
|
MECHANISM
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p6
|
Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
|
anakinra
|
TNF-blocking agent
|
EFFECT
|
Adalimumab_ddi.xml
|
DDI-DrugBank.d493.s2
|
DDI-DrugBank.d493.s2.p4
|
Avoid the concomitant use of chlorprothixene and tramadol (Ultram).
|
chlorprothixene
|
tramadol
|
ADVISE
|
Chlorprothixene_ddi.xml
|
DDI-DrugBank.d503.s3
|
DDI-DrugBank.d503.s3.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
salicylates
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p44
|
Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.
|
fexofenadine hydrochloride
|
aluminum
|
MECHANISM
|
Fexofenadine_ddi.xml
|
DDI-DrugBank.d466.s19
|
DDI-DrugBank.d466.s19.p6
|
Of particular importance, sufficient time must elapse before initiating TCAtreatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).
|
TCA
|
fluoxetine
|
ADVISE
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s20
|
DDI-DrugBank.d238.s20.p0
|
Anticholinergic agents: Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications.
|
ipratropium bromide
|
anticholinergic medications
|
EFFECT
|
Ipratropium_ddi.xml
|
DDI-DrugBank.d51.s2
|
DDI-DrugBank.d51.s2.p2
|
Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.
|
VIOXX
|
rifampin
|
MECHANISM
|
Rofecoxib_ddi.xml
|
DDI-DrugBank.d210.s25
|
DDI-DrugBank.d210.s25.p3
|
Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels.
|
theophylline
|
lansoprazole
|
ADVISE
|
Lansoprazole_ddi.xml
|
DDI-DrugBank.d431.s5
|
DDI-DrugBank.d431.s5.p0
|
If concomitant treatment with AXERT and an SSRI is clinically warranted, appropriate observation of the patient is advised.
|
AXERT
|
SSRI
|
ADVISE
|
Almotriptan_ddi.xml
|
DDI-DrugBank.d299.s7
|
DDI-DrugBank.d299.s7.p0
|
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.
|
phenobarbital
|
saquinavir
|
MECHANISM
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s30
|
DDI-DrugBank.d124.s30.p3
|
Chlorprothixene may increase the plasma-level of concomitantly given lithium.
|
Chlorprothixene
|
lithium
|
MECHANISM
|
Chlorprothixene_ddi.xml
|
DDI-DrugBank.d503.s0
|
DDI-DrugBank.d503.s0.p0
|
It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
|
photosensitizing agents
|
LEVULAN KERASTICK
|
EFFECT
|
Aminolevulinic acid_ddi.xml
|
DDI-DrugBank.d379.s1
|
DDI-DrugBank.d379.s1.p6
|
Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
|
clonidine
|
insulin
|
EFFECT
|
Insulin recombinant_ddi.xml
|
DDI-DrugBank.d313.s3
|
DDI-DrugBank.d313.s3.p6
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
clonazepam
|
valproate
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p365
|
therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.
|
Aprepitant
|
aprepitant
|
MECHANISM
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s34
|
DDI-DrugBank.d382.s34.p3
|
In addition to the interactions noted above, chronic ( 2 weeks) oral Cordarone administration impairs metabolism of phenytoin, dextromethorphan, and methotrexate.
|
Cordarone
|
dextromethorphan
|
NONE
|
Amiodarone_ddi.xml
|
DDI-DrugBank.d143.s62
|
DDI-DrugBank.d143.s62.p1
|
CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.
|
ethanol
|
ethanol
|
NONE
|
Eszopiclone_ddi.xml
|
DDI-DrugBank.d216.s0
|
DDI-DrugBank.d216.s0.p5
|
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
|
chloroquine
|
leflunomide
|
NONE
|
Abatacept_ddi.xml
|
DDI-DrugBank.d297.s2
|
DDI-DrugBank.d297.s2.p53
|
Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
|
aminoglycosides
|
zalcitabine
|
MECHANISM
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s18
|
DDI-DrugBank.d263.s18.p26
|
A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.
|
cisapride
|
ketoconazole
|
EFFECT
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s9
|
DDI-DrugBank.d237.s9.p0
|
Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.
|
pimozide
|
citalopram
|
EFFECT
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s13
|
DDI-DrugBank.d568.s13.p7
|
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
|
pure agonist opioid analgesic
|
Levo-Dromoran
|
ADVISE
|
Levorphanol_ddi.xml
|
DDI-DrugBank.d257.s6
|
DDI-DrugBank.d257.s6.p35
|
Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.
|
indomethacin
|
MIDAMOR
|
EFFECT
|
Amiloride_ddi.xml
|
DDI-DrugBank.d356.s6
|
DDI-DrugBank.d356.s6.p1
|
Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.
|
valdecoxib
|
fluconazole
|
MECHANISM
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s28
|
DDI-DrugBank.d328.s28.p1
|
MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.
|
MAO inhibitors
|
antihistamines
|
EFFECT
|
Carbinoxamine_ddi.xml
|
DDI-DrugBank.d389.s1
|
DDI-DrugBank.d389.s1.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
cyclosporin
|
ethosuximide
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p410
|
Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
|
sertraline
|
5-HT1 agonists
|
EFFECT
|
Frovatriptan_ddi.xml
|
DDI-DrugBank.d426.s3
|
DDI-DrugBank.d426.s3.p20
|
Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
|
foscarnet
|
HIVID
|
EFFECT
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s18
|
DDI-DrugBank.d263.s18.p23
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
phenytoin
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p38
|
Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.
|
dolasetron
|
cimetidine
|
MECHANISM
|
Dolasetron_ddi.xml
|
DDI-DrugBank.d42.s1
|
DDI-DrugBank.d42.s1.p3
|
Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1 agonists within 24 hours of each other is not recommended.
|
naratriptan
|
5-HT1 agonists
|
ADVISE
|
Naratriptan_ddi.xml
|
DDI-DrugBank.d478.s3
|
DDI-DrugBank.d478.s3.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
nortriptyline
|
quetiapine
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p888
|
Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.
|
Antacids
|
pseudoephedrine
|
MECHANISM
|
Azatadine_ddi.xml
|
DDI-DrugBank.d448.s6
|
DDI-DrugBank.d448.s6.p0
|
It was observed that MPTP induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by pargyline pretreatment.
|
MPTP
|
pargyline
|
EFFECT
|
3871245.xml
|
DDI-MedLine.d73.s2
|
DDI-MedLine.d73.s2.p0
|
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
sulfonylureas
|
salicylates
|
EFFECT
|
Glibenclamide_ddi.xml
|
DDI-DrugBank.d178.s0
|
DDI-DrugBank.d178.s0.p1
|
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
|
LEVSIN
|
amantadine
|
EFFECT
|
Hyoscyamine_ddi.xml
|
DDI-DrugBank.d142.s0
|
DDI-DrugBank.d142.s0.p1
|
It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
|
sulfonamides
|
LEVULAN KERASTICK
|
EFFECT
|
Aminolevulinic acid_ddi.xml
|
DDI-DrugBank.d379.s1
|
DDI-DrugBank.d379.s1.p26
|
Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
|
caffeine
|
CNS depressants
|
EFFECT
|
Butalbital_ddi.xml
|
DDI-DrugBank.d559.s1
|
DDI-DrugBank.d559.s1.p23
|
Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.
|
Fexofenadine
|
ketoconazole
|
NONE
|
Fexofenadine_ddi.xml
|
DDI-DrugBank.d466.s2
|
DDI-DrugBank.d466.s2.p1
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
protease inhibitors
|
Kadian
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p789
|
Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.
|
beta-blockers
|
clonidine
|
ADVISE
|
Betaxolol_ddi.xml
|
DDI-DrugBank.d489.s4
|
DDI-DrugBank.d489.s4.p0
|
Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);
|
Cisapride
|
antiarrhythmics
|
ADVISE
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s14
|
DDI-DrugBank.d237.s14.p0
|
The potential for increased sedation when guanfacine is given with other CNS-depressant drug should be appreciated.
|
guanfacine
|
CNS-depressant drug
|
EFFECT
|
Guanfacine_ddi.xml
|
DDI-DrugBank.d507.s0
|
DDI-DrugBank.d507.s0.p0
|
Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;
|
levobupivacaine
|
ketoconazole
|
MECHANISM
|
Levobupivacaine_ddi.xml
|
DDI-DrugBank.d320.s3
|
DDI-DrugBank.d320.s3.p3
|
When therapeutic concentrations of furosemide, propranolol, dipyridamole, warfarin, quinidine, or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered.
|
warfarin
|
naproxen
|
NONE
|
Nicardipine_ddi.xml
|
DDI-DrugBank.d468.s10
|
DDI-DrugBank.d468.s10.p16
|
Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
|
anticholinergic
|
meperidine
|
EFFECT
|
Biperiden_ddi.xml
|
DDI-DrugBank.d401.s0
|
DDI-DrugBank.d401.s0.p2
|
Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
|
cabergoline
|
lithium
|
NONE
|
Chlorpromazine_ddi.xml
|
DDI-DrugBank.d86.s1
|
DDI-DrugBank.d86.s1.p90
|
Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3.
|
Physostigmine
|
alcohol
|
EFFECT
|
6536292.xml
|
DDI-MedLine.d54.s8
|
DDI-MedLine.d54.s8.p0
|
Cyclosporine: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration.
|
Cyclosporine
|
TRICOR
|
NONE
|
Fenofibrate_ddi.xml
|
DDI-DrugBank.d283.s5
|
DDI-DrugBank.d283.s5.p2
|
Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors, including lisinopril.
|
NSAIDs
|
ACE inhibitors
|
EFFECT
|
Lisinopril_ddi.xml
|
DDI-DrugBank.d334.s7
|
DDI-DrugBank.d334.s7.p0
|
Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.
|
vaccines
|
corticosteroid
|
ADVISE
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s32
|
DDI-DrugBank.d314.s32.p0
|
Concomitant treatment with thrombolytics (eg, rt-PA or streptokinase) may: - increase the risk of bleeding complications - considerably enhance the effect of REFLUDAN on aPTT prolongation
|
streptokinase
|
REFLUDAN
|
NONE
|
Lepirudin_ddi.xml
|
DDI-DrugBank.d52.s0
|
DDI-DrugBank.d52.s0.p2
|
Synergism was observed when GL was combined with cefazolin against Bacillus subtilis and Klebsiella oxytoca.
|
GL
|
cefazolin
|
EFFECT
|
10319155.xml
|
DDI-MedLine.d84.s5
|
DDI-MedLine.d84.s5.p0
|
The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.
|
zalcitabine
|
magnesium
|
ADVISE
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s23
|
DDI-DrugBank.d263.s23.p0
|
Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.
|
valdecoxib
|
fluconazole
|
MECHANISM
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s29
|
DDI-DrugBank.d328.s29.p0
|
Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.
|
diclofenac
|
cyclosporine
|
EFFECT
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s4
|
DDI-DrugBank.d249.s4.p2
|
Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .
|
doxapram
|
monoamine oxidase inhibiting drugs
|
EFFECT
|
Doxapram_ddi.xml
|
DDI-DrugBank.d332.s0
|
DDI-DrugBank.d332.s0.p1
|
Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).
|
Isocarboxazid
|
disulfiram
|
ADVISE
|
Isocarboxazid_ddi.xml
|
DDI-DrugBank.d108.s0
|
DDI-DrugBank.d108.s0.p1
|
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
|
cisplatin
|
phenytoin
|
NONE
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s13
|
DDI-DrugBank.d263.s13.p39
|
- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
|
fluphenazine
|
Trilafon
|
NONE
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s21
|
DDI-DrugBank.d179.s21.p114
|
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
|
Lorazepam
|
phenothiazines
|
EFFECT
|
Lorazepam_ddi.xml
|
DDI-DrugBank.d18.s1
|
DDI-DrugBank.d18.s1.p2
|
Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.
|
antihistamines
|
heparin sodium
|
EFFECT
|
Heparin_ddi.xml
|
DDI-DrugBank.d488.s6
|
DDI-DrugBank.d488.s6.p14
|
In vitro, buspirone may displace less firmly bound drugs like digoxin.
|
buspirone
|
digoxin
|
MECHANISM
|
Buspirone_ddi.xml
|
DDI-DrugBank.d463.s8
|
DDI-DrugBank.d463.s8.p0
|
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
|
diuretics
|
contraceptives
|
NONE
|
Chlorpropamide_ddi.xml
|
DDI-DrugBank.d245.s4
|
DDI-DrugBank.d245.s4.p13
|
Furosemide may decrease arterial responsiveness to norepinephrine.
|
Furosemide
|
norepinephrine
|
EFFECT
|
Furosemide_ddi.xml
|
DDI-DrugBank.d231.s8
|
DDI-DrugBank.d231.s8.p0
|
Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.
|
Warfarin
|
warfarin
|
NONE
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s19
|
DDI-DrugBank.d123.s19.p2
|
Nevirapine and ketoconazole should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.
|
Nevirapine
|
ketoconazole
|
ADVISE
|
Nevirapine_ddi.xml
|
DDI-DrugBank.d270.s36
|
DDI-DrugBank.d270.s36.p0
|
No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.
|
aspirin
|
warfarin
|
NONE
|
Colestipol_ddi.xml
|
DDI-DrugBank.d345.s13
|
DDI-DrugBank.d345.s13.p16
|
Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, Duloxetine and thioridazine should not be co-administered.
|
Duloxetine
|
thioridazine
|
ADVISE
|
Duloxetine_ddi.xml
|
DDI-DrugBank.d548.s11
|
DDI-DrugBank.d548.s11.p2
|
However, co administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.
|
fexofenadine hydrochloride
|
ketoconazole
|
MECHANISM
|
Fexofenadine_ddi.xml
|
DDI-DrugBank.d466.s1
|
DDI-DrugBank.d466.s1.p0
|
Bromocriptine mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents.
|
Bromocriptine mesylate
|
dopamine antagonists
|
INT
|
Bromocriptine_ddi.xml
|
DDI-DrugBank.d272.s1
|
DDI-DrugBank.d272.s1.p0
|
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
|
Lorazepam
|
MAO inhibitors
|
EFFECT
|
Lorazepam_ddi.xml
|
DDI-DrugBank.d18.s1
|
DDI-DrugBank.d18.s1.p4
|
Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.
|
ketoconazole
|
lapatinib
|
MECHANISM
|
Lapatinib_ddi.xml
|
DDI-DrugBank.d135.s7
|
DDI-DrugBank.d135.s7.p2
|
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
|
VISTIDE
|
pentamidine
|
ADVISE
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s3
|
DDI-DrugBank.d260.s3.p6
|
Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
|
Bentiromide
|
thiazide diuretics
|
INT
|
Bentiromide_ddi.xml
|
DDI-DrugBank.d537.s0
|
DDI-DrugBank.d537.s0.p13
|
Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
|
Antacids
|
didanosine
|
NONE
|
Lomefloxacin_ddi.xml
|
DDI-DrugBank.d516.s3
|
DDI-DrugBank.d516.s3.p6
|
Interactions of cobalt and iron in absorption and retention.
|
cobalt
|
iron
|
MECHANISM
|
7599505.xml
|
DDI-MedLine.d34.s0
|
DDI-MedLine.d34.s0.p0
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.